[Lab] SGN cagri — VendorInvestigate came back 97.4% against a claimed 97.0%
SGN cagri — VendorInvestigate came back 97.4% against a claimed 97.0%, and before anyone asks: same batch throughout, single submission, no cherry-picking between services.
97.4% and 97.0% — those are the numbers, and they are the ones I am willing to defend.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
That is everything I have. The rest is opinion and I have tried to keep it out.
- SGSGN source pageSangon Biotech (Shanghai) Co., Ltd. · Shanghai · 95% here, rank 8 · shop at sangonbio.com →
nofollow and sponsored; nobody here is paid for it.best — the order this archive was captured in
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
The engineering problem was duration: native amylin is short-acting and aggregation-prone.
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
Correcting myself upthread: I gave the 15-week figure and the paper reports 64 weeks.
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
Standing reminder: nothing here is approved standalone, research material is not for human use, and no dosing schedules for other members.
- 1Why this compound is not simply another agonist, which is how it gets…6 comments in this branch · started by u/titration_marshal